Navigation Links
Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
Date:11/7/2007

f patients in the placebo arm (p<0.0001) at 24 weeks. Data from the two studies showed that more than half of patients experienced at least a 20% reduction in RA symptoms (ACR20) in the ACTEMRA plus DMARD therapies groups compared to the placebo plus DMARD therapies groups. ACTEMRA was generally well tolerated in both studies; the most common adverse events reported more frequently in the ACTEMRA arm were upper respiratory tract infections, headache, nasopharyngitis, and hypertension.

"It is vital that physicians have a variety of treatment options to offer patients to treat this debilitating and chronic disease," said Josef Smolen, M.D., lead investigator of the OPTION trial and Professor of Medicine at the University Clinic for Internal Medicine in Vienna, Austria. "ACTEMRA may offer a novel approach to help patients who may not be achieving sufficient relief from standard therapies like methotrexate."

About TOWARD Study

The TOWARD trial, a two-arm, double-blind, placebo controlled study, was designed to evaluate the safety and efficacy of ACTEMRA plus DMARDs compared to placebo plus DMARDs in RA patients. Patients were randomized to receive either ACTEMRA intravenously (8mg/kg) every four weeks plus DMARDs weekly or placebo infusions plus DMARDs weekly. The study treated 1,216 patients at 130 trial sites in 18 countries, including the United States.

About OPTION Study

In the OPTION trial, 623 patients were randomized to receive ACTEMRA intravenously (either 4mg/kg or 8mg/kg) every four weeks plus methotrexate weekly or placebo infusions plus methotrexate weekly. OPTION, a three-arm, double-blind, controlled study, evaluated the safety and efficacy of ACTEMRA plus methotrexate compared to placebo plus methotrexate in RA patients. The study was conducted in 73 trial sites in 17 countries outside the United States.

Study Results

Both TOWARD and OPTION studies showed that at 24 weeks significantly more patients achieved a 20%
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos,Pharmaceuticals, ... the next generation of antiviral,therapeutic products, today ... that HIV resistant to Protease Inhibitors (PI) ... resistance to the HIV,maturation inhibitor bevirimat in ...
... Taxotere(R) and on three investigational,agents (VEGF Trap, S-1 ... ASCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ ... abstracts,indicative of its oncology commitment have been accepted ... of Clinical Oncology,(ASCO) in Chicago, Illinois (June 1-5, ...
Cached Medicine Technology:Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 2Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:7/24/2014)... rats bearing human breast tumors, exposure to dim light ... cancer drug tamoxifen, according to data published in ... for Cancer Research. The negative effects of dim light ... a melatonin supplement during the night. , "Resistance to ... receptor-positive breast cancer," said Steven M. Hill, PhD, professor ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap Manchester ... Authority Field on July 26th. For the past four years, the ... the best club teams from around the world to North America ... weeks after its completion, fans – new and old alike – ... in the world compete. Some of these players were already members ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District Court, ... order for plaintiff medical information covered by the ... to the July 16th Order, U.S. District Judge ... for Fresenius Medical Care the right to receive ...
(Date:7/24/2014)... Association Executives (ASAE) announced its 2014 Power of A ... Society of Anesthesiologists (ASA). , The ASA Global ... Gold Award, one of the top honors from ASAE. ... the world through education on the global anesthesia crisis ... , ASA was also honored with a Power of ...
(Date:7/24/2014)... July 24, 2014 Pools and beaches are ... water can be dangerous, especially for small children, so ... safety. , According to the Centers for Disease Control and ... most at risk for water-related injuries and deaths. It’s important ... around water, so Amica is offering the following tips from ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... book, written by Dr. Vardit Rispler-Chaim of the Department ... Haifa, analyzes attitudes to people with various ... Middle Ages and the modern era. , In the ... and often within broad topics such as religious duties, ...
... focus on issues most critical to health care ... selected as new survey vendor, WASHINGTON, Dec. 12 ... non-profit organization of employer-based,health coalitions, released its 2008 eValue8(TM) ... health care purchasers to compare,the quality and efficiency of ...
... Dec. 12 INVEGA(TM) (paliperidone),Extended-Release Tablets showed ... open-label extension (OLE) study, according to a ... improved or,were stable, on average, over this ... to evaluate the long-term safety of INVEGA, ...
... had harder time fighting gum disease , , WEDNESDAY, ... harder to fight infections, and a weakened immune response ... Boston University researchers. , In experiments with mice infected ... had less ability to battle gum infection than their ...
... and Providers, AUSTIN, Texas, Dec. 12 ... report, U.S. taxpayers are annually defrauded of,about $60 ... health,care providers. A new system developed by S3 ... significant impact on reducing Medicare,and Medicaid fraud with ...
... by the,positive results of the 2007 Monitoring the Future ... in the right direction,with significant declines in overall teen ... for all measured age groups marking steady long-term,reductions in ... MTF, now in its 33rd year, is an ...
Cached Medicine News:Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 2Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 4Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 5Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 6Health News:Obesity Weakens Immune Response 2Health News:Technology can Dramatically Reduce Billions of Dollars in Medicaid, Medicare Fraud 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 4
New!...
... I/A unit for planned ECCE with ... control). Independent irrigation, suction, reflux possible ... surgeon to control all critical functions. ... simultaneously. Preset and actual vacuum level ...
... Anterior and Posterior segment surgeries Vitrectomy-Lensectomy ... Ventury or Peristaltic Linear Aspiration. Interchangeable ... specific cutting action. Easy to read ... Cutting speed-variable from 1- 600 cuts ...
...
Medicine Products: